<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intravascular large B cell lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intravascular large B cell lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intravascular large B cell lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Almut Böer-Auer, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intravascular large B cell lymphoma (IVLBCL) is a rare subtype of B cell non-Hodgkin lymphoma characterized by proliferation of lymphoma cells within the lumina of small blood vessels, particularly capillaries and post-capillary venules. IVLBCL manifests no obvious lymphadenopathy, extravascular tumor mass, or readily observable circulating lymphoma cells in peripheral blood.</p><p>This type of lymphoma was previously described as intravascular lymphomatosis, angiotropic large cell lymphoma, and malignant angioendotheliomatosis. Criteria for diagnosis and classification of IVLBCL are the same in both the International Consensus Classification [<a href="#rid1">1</a>] and the World Health Organization 5<sup>th</sup> edition [<a href="#rid2">2</a>].</p><p>The clinical presentation of IVLBCL is highly variable and often includes symptoms related to organ dysfunction caused by occlusion of blood vessels. Particularly in the past, diagnosis of IVLBCL was usually only recognized at autopsy. Heightened awareness has resulted in more patients being diagnosed with IVLBCL during life, thereby allowing for treatment.</p><p>The clinical presentation, diagnosis, and treatment of IVLBCL are discussed in this topic. </p><p>Diagnosis and classification of other subtypes of large B cell lymphoma are presented separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>IVLBCL is a rare subtype of large cell lymphoma; the true incidence is unknown. The median age at diagnosis is in the sixth to seventh decades; there is no sex predilection [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Patients can present with a bewildering array of symptoms caused by the occlusion of small vessels. A peculiar aspect of IVLBCL is the lack of lymphadenopathy, which is a general characteristic of other types of malignant lymphomas.</p><p class="headingAnchor" id="H4"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Constitutional B symptoms (ie, fever, night sweats, and weight loss) are seen in the majority of patients (55 to 85 percent) [<a href="#rid3">3-5</a>]. The clinical presentation appears to differ by country of origin, although individual presentations vary tremendously and virtually any organ can be involved:</p><p class="bulletIndent1"><span class="glyph">●</span>In Western countries, patients present most commonly with symptoms related to involvement of the central nervous system (39 to 76 percent) and skin (17 to 39 percent) [<a href="#rid3">3,6</a>]. Fever, skin lesions, and prominent, rapidly progressive neurologic signs (eg, dementia, progressive cerebral vascular accident, peripheral neuropathy) are frequent [<a href="#rid3">3,6-8</a>]. Less commonly involved tissues include the bone marrow (32 percent), spleen (26 percent), and liver (26 percent) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Asia, neurologic symptoms (27 percent) and cutaneous lesions (15 percent) are less common than in Western countries [<a href="#rid9">9</a>]. Patients frequently present with involvement of the bone marrow (75 percent), spleen (67 percent), and liver (55 percent) [<a href="#rid4">4,10-12</a>]. Hemophagocytic syndrome, a condition stemming from systemic macrophage activation that is associated with B symptoms and the hemophagocytosis of red cells, white blood cells, and/or platelets, can be seen [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/8384.html" rel="external">"Treatment and prognosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p></p><p>There is a cutaneous variant of IVLBCL that presents with symptoms limited to the skin [<a href="#rid3">3</a>]. This variant is seen more frequently in Western countries (24 percent) and is rare in Asia (3 percent) [<a href="#rid13">13</a>]. Patients are mostly younger females with good performance status [<a href="#rid3">3</a>]. Skin lesions are most commonly nodules, plaques, or macules of red to grayish-blue color on the leg (35 percent), thigh (41 percent), and trunk (31 percent) [<a href="#rid14">14</a>]. Telangiectasia, edema, and pain are often seen concomitantly, making it difficult to differentiate cutaneous IVLBCL from inflammatory skin diseases such as thrombophlebitis or erythema nodosum. To date, no criteria enable clinical distinction between IVLBCL restricted to the skin and skin lesions concurrent with IVLBCL in other organs.</p><p class="headingAnchor" id="H5"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Patients often present with the following laboratory abnormalities [<a href="#rid3">3,6,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum lactate dehydrogenase (LDH), beta-2 microglobulin, elevated sedimentation rate, C-reactive protein</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Altered hepatic, renal, or thyroid function</p><p class="bulletIndent1"><span class="glyph">●</span>Serum monoclonal protein</p><p></p><p>Patients from Western countries and Asian countries differ in their rates of thrombocytopenia (29 versus 76 percent) and hypoalbuminemia (18 versus 84 percent).</p><p>Anti-proteinase-3-anti-neutrophil cytoplasmic antibodies (ANCA) have been reported in patients with IVLBCL, which may be related to endothelial damage; this finding may delay the diagnosis [<a href="#rid15">15-17</a>].</p><p class="headingAnchor" id="H6"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Involved tissues demonstrate neoplastic lymphoid cells lodged in the capillaries and post-capillary venules  (<a class="graphic graphic_picture graphicRef62103" href="/d/graphic/62103.html" rel="external">picture 1</a>). Malignant cells also may be found, albeit rarely, in cerebrospinal fluid or peripheral blood; bone marrow involvement varies with geographic location [<a href="#rid18">18</a>]. Like other subtypes of large cell lymphoma, the morphology varies; most often the lymphoid cells are large in size, have vesicular nuclei and prominent nucleoli  (<a class="graphic graphic_picture graphicRef81094" href="/d/graphic/81094.html" rel="external">picture 2</a>). Frequent mitotic figures are seen. Ki-67 staining demonstrates high proliferative activity. Immunophenotyping usually identifies the cells to be mature B cells; such cases can be considered an intravascular variant of diffuse large B cell lymphoma. Rare cases of IVLBCL are of T cell or NK cell origin [<a href="#rid19">19,20</a>]. A subset of the cases associated with hemophagocytic syndrome is positive for Epstein-Barr virus infection. An intravascular gamma-delta T cell lymphoma has been described [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Pathology'</a> and  <a class="medical medical_review" href="/d/html/4703.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Diagnosis'</a>.)</p><p>In the skin, intravascular neoplastic lymphoid cells may be accompanied by reactive perivascular infiltrates of small lymphocytes and plasma cells  (<a class="graphic graphic_picture graphicRef81381" href="/d/graphic/81381.html" rel="external">picture 3</a>) [<a href="#rid14">14</a>]. Vessels containing lymphoma cells may be very few in number and can be located anywhere in the skin and subcutaneous tissue.</p><p>Relatively little is known about the genetics of IVLBCL. Case studies have identified diverse translocations involving oncogenes implicated in other B cell lymphomas, including <em>BCL2, BCL6, </em>and<em> CCND1</em> (cyclin D1) [<a href="#rid22">22-24</a>]. A series of seven cases with abnormal karyotypes revealed complex chromosomal aberrations in all cases, including recurrent abnormalities involving chromosome 6q13, chromosome 8p11.2, and chromosome 19q13 [<a href="#rid25">25</a>]. Targeted exon sequencing of a series of 25 B cell tumors detected mutations in genes that encode B cell receptor signaling pathway components, particularly <em>MYD88</em> (44 percent) and CD79B (26 percent) [<a href="#rid26">26</a>]; this finding is consistent with an origin from a non-germinal center B cell. Analysis of the genetics of 21 additional cases of IVLBCL based on sequencing of cell-free DNA from peripheral blood confirmed the presence of frequent mutations in <em>MYD88</em> (57 percent) and CD79B (67 percent) and also identified 38 percent with mutations involving the genes encoding PD-L1 or PD-L2, suggesting that immune evasion may have a pathogenic role in IVLBCL [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>IVLBCL should be suspected in patients with unexplained constitutional symptoms, rapidly progressive neurologic findings, and skin lesions that resemble inflammatory skin conditions.</p><p>The diagnosis is made by identifying large lymphoma cells within small to medium blood vessels [<a href="#rid13">13</a>].</p><p>When the diagnosis of IVLBCL is suspected, biopsies of involved skin, senile hemangiomata (if present), or random biopsies of apparently normal skin may be diagnostic [<a href="#rid28">28-38</a>]. Incisional biopsies are preferable to punch biopsies [<a href="#rid39">39</a>]. Deep skin biopsies must be performed because involved blood vessels are mostly in the subcutaneous fat [<a href="#rid14">14</a>]. The yield from random skin biopsies is controversial, but some experts advocate that random skin biopsies should include at least three specimens (eg, from both thighs and abdomen) [<a href="#rid35">35,40-42</a>]. In cases of suspected brain involvement of intravascular lymphoma, skin biopsies should be performed before brain biopsies [<a href="#rid43">43</a>]. </p><p>Other sites may be biopsied if skin biopsies are non-diagnostic, especially if there is evidence of organ dysfunction. Case reports describe diagnostic specimens from liver, lung, and brain [<a href="#rid13">13,28,32,44</a>]. Although commonly involved in other subtypes of lymphoma, bone marrow, lymph nodes, peripheral blood, and cerebrospinal fluid are often uninvolved in IVLBCL [<a href="#rid45">45</a>]. Involvement of these sites can be subtle, and stains for lymphoid markers (eg, CD20) may detect rare tumor cells within small vessels that are missed by morphology alone. As discussed above, bone marrow involvement is more frequent in the so-called Asian variant of IVLBCL. (See <a class="local">'Symptoms'</a> above.)</p><p>Immunophenotyping of intravascular lymphoid cells is required to distinguish IVLBCL from T cell or NK cell IVLBCL. The rare NK/T cell phenotype (positive for CD2, cytoplasmic CD3, CD56 and cytotoxic proteins such as granzyme B, and negative for CD20, surface CD3, CD4, CD8, and CD5) reveals lymphoma cells that are positive for Epstein-Barr virus antigens; such cases usually follow an aggressive course [<a href="#rid46">46,47</a>]. Ki-67 proliferation index was reported to be an independent risk factor for duration of survival [<a href="#rid48">48</a>]. Double expressor status (ie, C-MYC plus BCL2) may also be a prognostic indicator, with higher mortality compared with non-double expressors [<a href="#rid49">49</a>]. </p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>IVLBCL must be distinguished from various inflammatory and immune reactions and from other lymphomas.</p><p>On occasion, clusters of activated lymphocytes may be observed within the post-capillary venules of tissues involved in inflammatory or immune reactions, particularly the lymph nodes. On purely morphologic grounds, these may be difficult to distinguish from focal involvement by IVLBCL. As noted above, however, most patients with IVLBCL have systemic constitutional symptoms, laboratory abnormalities, and evidence of organ dysfunction, all of which are typically associated with extensive intravascular disease in extranodal organs, allowing for the diagnosis to be established on clinicopathologic grounds. </p><p>Intralymphatic histiocytosis is a reactive condition of macrophages associated with rheumatoid arthritis that may present with clinical lesions like those of IVLBCL and with intravascular proliferations of large cells. Intralymphatic histiocytosis can be differentiated from IVLBCL by immunophenotyping, which will demonstrate expression of macrophage-specific markers (eg, CD68) and absence of lymphoid markers [<a href="#rid50">50</a>].</p><p>A benign atypical intravascular CD30+ T cell proliferation was described, in which CD30+ polyclonal T cells (Epstein-Barr virus negative) are found within lymphatics in close vicinity to ulceration or an inflammatory skin disease [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H9"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have impact on treatment options. In general, the pretreatment evaluation is the same as that performed for patients with diffuse large B cell lymphoma. This is presented in detail separately. Of note, patients with intravascular large B cell lymphoma have a high rate of central nervous system involvement. As such, we typically evaluate the central nervous system with a lumbar puncture and magnetic resonance imaging (MRI) of the brain. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Pretreatment evaluation'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of IVLBCL includes both systemic therapy and treatments directed at the central nervous system.</p><p class="headingAnchor" id="H11"><span class="h2">Systemic therapy</span><span class="headingEndMark"> — </span>Due to the presence of lymphoma cells within the blood vessels, all cases of IVLBCL are considered disseminated and are therefore treated as advanced disease. Only case reports and retrospective analyses have been reported on the treatment of IVLBCL. Most patients are treated with regimens used for the treatment of diffuse large B cell lymphoma. Specifically, a combination of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> with the recombinant anti-CD20 antibody <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (R-CHOP) is the most commonly employed treatment  (<a class="graphic graphic_table graphicRef63586" href="/d/graphic/63586.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a>.)</p><p>Anthracycline-based chemotherapy (eg, CHOP, CHOP-R) can achieve response rates in &gt;60 percent and estimated three-year overall survival &gt;30 percent; long-term survival appears to be possible [<a href="#rid3">3,5,6,13,30,52-55</a>].</p><p>Support for the use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> plus anthracycline-based chemotherapy comes from case reports and retrospective studies [<a href="#rid3">3,5,13,30,52-55</a>]. The largest retrospective analysis of treatment included 106 patients with newly diagnosed IVLBCL treated either with chemotherapy alone (57 patients) or chemotherapy plus rituximab (49 patients) [<a href="#rid5">5</a>]. Approximately 83 percent of the patients received CHOP or CHOP-like chemotherapy with or without rituximab. There was no difference in the rate of treatment-related deaths. At a median follow-up of 18 months, patients treated with chemotherapy plus rituximab had significantly higher rates of:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete response (82 versus 51 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Two-year progression-free survival (56 versus 27 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Two-year overall survival (66 versus 46 percent)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">CNS directed therapy</span><span class="headingEndMark"> — </span>Central nervous system (CNS) involvement is seen in 30 to 40 percent of patients with IVLBCL at diagnosis and occurs in another 25 percent of patients during follow-up [<a href="#rid9">9</a>]. Systemic therapy with R-CHOP does not sufficiently penetrate the CNS, therefore patients with IVLBCL also require therapies directed towards the CNS, either as prophylaxis for or treatment of CNS involvement. As mentioned above, the pretreatment evaluation includes a lumbar puncture and MRI of the brain. CNS-directed therapy is determined based on the results of these tests:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients without tumor cells in the cerebrospinal fluid (CSF) and normal imaging by MRI, we administer CNS prophylaxis. (See  <a class="medical medical_review" href="/d/html/89417.html" rel="external">"Secondary central nervous system lymphoma: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with secondary involvement of the brain or spinal cord at the time of diagnosis, we administer specific treatment targeting these areas. Such treatment varies based on the exact disease site, but can include intrathecal chemotherapy, systemic high dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and/or radiation to the sites of involvement. The treatment of CNS involvement is presented in detail separately. (See  <a class="medical medical_review" href="/d/html/4720.html" rel="external">"Secondary central nervous system lymphoma: Clinical features and diagnosis"</a>.)</p><p></p><p>Patients with neurologic compromise from spinal cord compression require urgent therapy. The timing of chemotherapy and radiation therapy is controversial; however, many patients are treated with radiation therapy prior to receiving systemic therapy. The benefit of intrathecal therapy, particularly in the presence of a normal spinal fluid evaluation, is unclear. (See  <a class="medical medical_review" href="/d/html/2820.html" rel="external">"Treatment and prognosis of neoplastic epidural spinal cord compression"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">EVALUATION OF RESPONSE</span><span class="headingEndMark"> — </span>One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). Positron emission tomography/computed tomography (PET/CT) should be obtained six to eight weeks after completion of chemotherapy and 12 weeks after the completion of radiation therapy [<a href="#rid56">56-58</a>]. PET/CT imaging obtained earlier than this is likely to demonstrate increased uptake due to an inflammatory reaction to treatment.</p><p>Given its unusual initial presentation and location of disease, the response criteria used for other types of non-Hodgkin lymphoma may not apply. Instead, prospective studies have used the following criteria for response [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete response – Disappearance of all clinical symptoms and radiographic or laboratory abnormalities, including bone marrow involvement, observed at diagnosis and the absence of any new abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progressive disease – Appearance of new abnormalities associated with the disease or evident deterioration of the initial abnormalities associated with the disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stable disease – Failure to achieve a complete response and lack of progressive disease.</p><p></p><p>Relapsed disease occurs when there is progression of the disease after an initial complete response.</p><p class="headingAnchor" id="H14"><span class="h1">PATIENT FOLLOW-UP</span><span class="headingEndMark"> — </span>Although follow-up data are scarce, relapses may be more common in those with central nervous system involvement and less common in those with cutaneous involvement [<a href="#rid13">13</a>]. When the disease is restricted to the skin, the prognosis seems to be favorable [<a href="#rid14">14</a>].</p><p>Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends on the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p>Our approach to patient surveillance is to schedule patient visits every three months during the first year, every three to six months during the second year, and every six months starting two years after complete response. At these visits we perform a history and physical examination, complete blood count, chemistries, and lactate dehydrogenase. We do perform CT scans at months 6, 12, 18, 24, 30 or 36, and then yearly until five years after attainment of a complete remission. No more imaging is performed after five years unless an abnormality suggests the possibility relapse, or the patient requests it.</p><p>Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. (See  <a class="medical medical_review" href="/d/html/4708.html" rel="external">"Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Intravascular large B cell lymphoma (IVLBCL) is a rare subtype of B cell non-Hodgkin lymphoma characterized by the proliferation of lymphoma cells within the lumina of small blood vessels, particularly capillaries and post-capillary venules, without an obvious extravascular tumor mass or detectable circulating tumor cells in the peripheral blood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Patients present with a bewildering variety of symptoms caused by the occlusion of small vessels. Common presentations include constitutional symptoms (eg, fever, night sweats, weight loss), rapidly progressive neurologic signs (eg, dementia, progressive cerebral vascular accident, peripheral neuropathy), and skin lesions that resemble inflammatory skin conditions (eg, thrombophlebitis, erythema nodosum). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – IVLBCL should be suspected in patients with unexplained constitutional symptoms, rapidly progressive neurologic findings, and/or skin lesions that resemble inflammatory skin conditions. </p><p></p><p class="bulletIndent1">Diagnosis is based on identification of large B cell lymphoma cells in small to medium blood vessels from a biopsy of involved skin, senile hemangiomata (if present), or random biopsies of apparently normal skin. If this does not yield a diagnosis, biopsy of other sites of suspected involvement may be undertaken, as appropriate. (See <a class="local">'Diagnosis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Autoimmune/collagen diseases and infections can cause similar nonspecific symptoms (eg, fever, malaise, dyspnea) but no lymphadenopathy or tumor masses. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – All patients with IVLBCL require evaluation for central nervous system (CNS) involvement by lumbar puncture and magnetic resonance imaging, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Central nervous system (CNS) evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment includes both systemic therapy and therapy directed at the CNS. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic</strong> <strong>therapy</strong> – Systemic treatment of IVLBCL is like that for diffuse large B cell lymphoma, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>CNS</strong> – Management is guided by findings from the evaluation of the CNS:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No documented CNS involvement</strong> – For patients with no documented CNS involvement, we provide CNS prophylaxis as discussed separately. (See  <a class="medical medical_review" href="/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Central nervous system (CNS) evaluation'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>CNS involvement</strong> – Treatment of documented CNS involvement varies among institutions but generally involves intrathecal chemotherapy, with or without high-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and/or radiation therapy. (See  <a class="medical medical_review" href="/d/html/89417.html" rel="external">"Secondary central nervous system lymphoma: Treatment and prognosis"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 2004; 127:173.</a></li><li><a class="nounderline abstract_t">Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007; 109:478.</a></li><li><a class="nounderline abstract_t">Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008; 26:3189.</a></li><li><a class="nounderline abstract_t">Brunet V, Marouan S, Routy JP, et al. Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports. Medicine (Baltimore) 2017; 96:e5985.</a></li><li><a class="nounderline abstract_t">Chapin JE, Davis LE, Kornfeld M, Mandler RN. Neurologic manifestations of intravascular lymphomatosis. Acta Neurol Scand 1995; 91:494.</a></li><li><a class="nounderline abstract_t">Detsky ME, Chiu L, Shandling MR, et al. Clinical problem-solving. Heading down the wrong path. N Engl J Med 2006; 355:67.</a></li><li><a class="nounderline abstract_t">Shimada K, Murase T, Matsue K, et al. Central nervous system involvement in intravascular large B-cell lymphoma: A retrospective analysis of 109 patients. Cancer Sci 2010; 101:1480.</a></li><li><a class="nounderline abstract_t">Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 2000; 111:826.</a></li><li><a class="nounderline abstract_t">Kojima K, Kaneda K, Yasukawa M, et al. Specificity of polymerase chain reaction-based clonality analysis of immunoglobulin heavy chain gene rearrangement for the detection of bone marrow infiltrate in B-cell lymphoma-associated haemophagocytic syndrome. Br J Haematol 2002; 119:616.</a></li><li><a class="nounderline abstract_t">Narimatsu H, Morishita Y, Saito S, et al. Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases. Leuk Lymphoma 2004; 45:1611.</a></li><li><a class="nounderline abstract_t">Ponzoni M, Ferreri AJ, Campo E, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007; 25:3168.</a></li><li><a class="nounderline abstract_t">Röglin J, Böer A. Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin. Br J Dermatol 2007; 157:16.</a></li><li><a class="nounderline abstract_t">Tsuda M, Nakashima Y, Ikeda M, et al. Intravascular Large B-Cell Lymphoma Complicated by Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that was Successfully Treated with Rituximab-Containing Chemotherapy. J Clin Exp Hematop 2015; 55:39.</a></li><li><a class="nounderline abstract_t">Sugiyama A, Kobayashi M, Daizo A, et al. Diffuse Cerebral Vasoconstriction in a Intravascular Lymphoma Patient with a High Serum MPO-ANCA Level. Intern Med 2017; 56:1715.</a></li><li><a class="nounderline abstract_t">Shinkawa Y, Hatachi S, Yagita M. Intravascular large B-cell lymphoma with a high titer of proteinase-3-anti-neutrophil cytoplasmic antibody mimicking granulomatosis with polyangiitis. Mod Rheumatol 2019; 29:195.</a></li><li><a class="nounderline abstract_t">Cobcroft R. Images in haematology. Diagnosis of angiotropic large B-cell lymphoma from a peripheral blood film. Br J Haematol 1999; 104:429.</a></li><li><a class="nounderline abstract_t">Williams G, Foyle A, White D, et al. Intravascular T-cell lymphoma with bowel involvement: case report and literature review. Am J Hematol 2005; 78:207.</a></li><li><a class="nounderline abstract_t">Song DE, Lee MW, Ryu MH, et al. Intravascular large cell lymphoma of the natural killer cell type. J Clin Oncol 2007; 25:1279.</a></li><li><a class="nounderline abstract_t">Martinez-Escala ME, Guggina LM, Cotliar J, et al. Cutaneous Involvement in a Case of Intravascular T-Cell Lymphoma With a γδ Phenotype. Am J Dermatopathol 2016; 38:e27.</a></li><li><a class="nounderline abstract_t">Vieites B, Fraga M, Lopez-Presas E, et al. Detection of t(14;18) translocation in a case of intravascular large B-cell lymphoma: a germinal centre cell origin in a subset of these lymphomas? Histopathology 2005; 46:466.</a></li><li><a class="nounderline abstract_t">Cui J, Liu Q, Cheng Y, et al. An intravascular large B-cell lymphoma with a t(3;14)(q27;q32) translocation. J Clin Pathol 2014; 67:279.</a></li><li><a class="nounderline abstract_t">Khoury H, Lestou VS, Gascoyne RD, et al. Multicolor karyotyping and clinicopathological analysis of three intravascular lymphoma cases. Mod Pathol 2003; 16:716.</a></li><li><a class="nounderline abstract_t">Fujikura K, Yamashita D, Yoshida M, et al. Cytogenetic complexity and heterogeneity in intravascular lymphoma. J Clin Pathol 2021; 74:244.</a></li><li><a class="nounderline abstract_t">Schrader AMR, Jansen PM, Willemze R, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood 2018; 131:2086.</a></li><li><a class="nounderline abstract_t">Shimada K, Yoshida K, Suzuki Y, et al. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood 2021; 137:1491.</a></li><li><a class="nounderline abstract_t">Ganguly S. Acute intracerebral hemorrhage in intravascular lymphoma: a serious infusion related adverse event of rituximab. Am J Clin Oncol 2007; 30:211.</a></li><li><a class="nounderline abstract_t">Kiyohara T, Kumakiri M, Kobayashi H, et al. A case of intravascular large B-cell lymphoma mimicking erythema nodosum: the importance of multiple skin biopsies. J Cutan Pathol 2000; 27:413.</a></li><li><a class="nounderline abstract_t">Gill S, Melosky B, Haley L, ChanYan C. Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. Am J Med 2003; 114:56.</a></li><li><a class="nounderline abstract_t">Odawara J, Asada N, Aoki T, et al. 18F-Fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma. Br J Haematol 2007; 136:684.</a></li><li><a class="nounderline abstract_t">Martusewicz-Boros M, Wiatr E, Radzikowska E, et al. Pulmonary intravascular large B-cell lymphoma as a cause of severe hypoxemia. J Clin Oncol 2007; 25:2137.</a></li><li><a class="nounderline abstract_t">Asada N, Odawara J, Kimura S, et al. Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc 2007; 82:1525.</a></li><li><a class="nounderline abstract_t">Le EN, Gerstenblith MR, Gelber AC, et al. The use of blind skin biopsy in the diagnosis of intravascular B-cell lymphoma. J Am Acad Dermatol 2008; 59:148.</a></li><li><a class="nounderline abstract_t">Pongpudpunth M, Rattanakaemakorn P, Fleischer AB Jr. Usefulness of Random Skin Biopsy as a Diagnostic Tool of Intravascular Lymphoma Presenting With Fever of Unknown Origin. Am J Dermatopathol 2015; 37:686.</a></li><li><a class="nounderline abstract_t">Adachi Y, Kosami K, Mizuta N, et al. Benefits of skin biopsy of senile hemangioma in intravascular large B-cell lymphoma: A case report and review of the literature. Oncol Lett 2014; 7:2003.</a></li><li><a class="nounderline abstract_t">Matsue K, Abe Y, Kitadate A, et al. Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood 2019; 133:1257.</a></li><li><a class="nounderline abstract_t">Rozenbaum D, Tung J, Xue Y, et al. Skin biopsy in the diagnosis of intravascular lymphoma: A retrospective diagnostic accuracy study. J Am Acad Dermatol 2021; 85:665.</a></li><li><a class="nounderline abstract_t">Enzan N, Kitadate A, Tanaka A, Matsue K. Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: a clinicopathological study of 25 patients. Br J Dermatol 2019; 181:200.</a></li><li><a class="nounderline abstract_t">Cho HG, Sheu SL, Kuo KY, et al. Limited Role of Random Skin Biopsy in the Diagnosis of Intravascular Lymphoma in Adult Patients with Hemophagocytic Lymphohistiocytosis. Acta Haematol 2017; 138:33.</a></li><li><a class="nounderline abstract_t">Sitthinamsuwan P, Chinthammitr Y, Pattanaprichakul P, Sukpanichnant S. Random skin biopsy in the diagnosis of intravascular lymphoma. J Cutan Pathol 2017; 44:729.</a></li><li><a class="nounderline abstract_t">Arai T, Kato Y, Funaki M, et al. Three Cases of Intravascular Large B-Cell Lymphoma Detected in a Biopsy of Skin Lesions. Dermatology 2016; 232:185.</a></li><li><a class="nounderline abstract_t">Yamada E, Ishikawa E, Watanabe R, et al. Random Skin Biopsies Before Brain Biopsy for Intravascular Large B-Cell Lymphoma. World Neurosurg 2019; 121:e364.</a></li><li><a class="nounderline abstract_t">Yamada S, Nishii R, Oka S, et al. FDG-PET a pivotal imaging modality for diagnosis of stroke-onset intravascular lymphoma. Arch Neurol 2010; 67:366.</a></li><li class="breakAll">Gatter KC, Warnke RA. Intravascular large B-cell lymphoma. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.177.</li><li><a class="nounderline abstract_t">Alhumidi A. Cutaneous Intravascular NK/T-cell lymphoma mimic panniculitis clinically, case report and literature brief review. Diagn Pathol 2015; 10:107.</a></li><li><a class="nounderline abstract_t">Wang L, Chen S, Ma H, et al. Intravascular NK/T-cell lymphoma: a report of five cases with cutaneous manifestation from China. J Cutan Pathol 2015; 42:610.</a></li><li><a class="nounderline abstract_t">Liu Y, Ma Y, Zhou H, et al. Analysis of clinicopathological features and prognostic factors of non-Hodgkin's intravascular large B-cell lymphoma. Oncol Lett 2020; 20:43.</a></li><li><a class="nounderline abstract_t">Boonsakan P, Iamsumang W, Chantrathammachart P, et al. Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study. Biomed Res Int 2020; 2020:1350820.</a></li><li><a class="nounderline abstract_t">Requena L, El-Shabrawi-Caelen L, Walsh SN, et al. Intralymphatic histiocytosis. A clinicopathologic study of 16 cases. Am J Dermatopathol 2009; 31:140.</a></li><li><a class="nounderline abstract_t">Kempf W, Keller K, John H, Dommann-Scherrer C. Benign atypical intravascular CD30+ T-cell proliferation: a recently described reactive lymphoproliferative process and simulator of intravascular lymphoma: report of a case associated with lichen sclerosus and review of the literature. Am J Clin Pathol 2014; 142:694.</a></li><li><a class="nounderline abstract_t">Tsukadaira A, Okubo Y, Ogasawara H, et al. Chromosomal aberrations in intravascular lymphomatosis. Am J Clin Oncol 2002; 25:178.</a></li><li><a class="nounderline abstract_t">Bouzani M, Karmiris T, Rontogianni D, et al. Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy. Oncologist 2006; 11:923.</a></li><li><a class="nounderline abstract_t">Koizumi M, Nishimura M, Yokota A, et al. Successful treatment of intravascular malignant lymphomatosis with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27:1101.</a></li><li><a class="nounderline abstract_t">Ferreri AJ, Dognini GP, Govi S, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol 2008; 26:5134.</a></li><li><a class="nounderline abstract_t">Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.</a></li><li><a class="nounderline abstract_t">Shimada K, Kosugi H, Shimada S, et al. Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Int J Hematol 2008; 88:149.</a></li><li><a class="nounderline abstract_t">Hoshino A, Kawada E, Ukita T, et al. Usefulness of FDG-PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin. Am J Hematol 2004; 76:236.</a></li></ol></div><div id="topicVersionRevision">Topic 4738 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15461623" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985183" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18506023" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28151891" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7572046" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neurologic manifestations of intravascular lymphomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16822998" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical problem-solving. Heading down the wrong path.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20412122" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122144" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12437634" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Specificity of polymerase chain reaction-based clonality analysis of immunoglobulin heavy chain gene rearrangement for the detection of bone marrow infiltrate in B-cell lymphoma-associated haemophagocytic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15370213" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577023" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17506787" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26106006" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intravascular Large B-Cell Lymphoma Complicated by Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that was Successfully Treated with Rituximab-Containing Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28674364" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diffuse Cerebral Vasoconstriction in a Intravascular Lymphoma Patient with a High Serum MPO-ANCA Level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27398728" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intravascular large B-cell lymphoma with a high titer of proteinase-3-anti-neutrophil cytoplasmic antibody mimicking granulomatosis with polyangiitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086773" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Images in haematology. Diagnosis of angiotropic large B-cell lymphoma from a peripheral blood film.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15726592" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intravascular T-cell lymphoma with bowel involvement: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401019" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Intravascular large cell lymphoma of the natural killer cell type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26460624" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cutaneous Involvement in a Case of Intravascular T-Cell Lymphoma With aγδPhenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15810961" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Detection of t(14;18) translocation in a case of intravascular large B-cell lymphoma: a germinal centre cell origin in a subset of these lymphomas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24357441" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : An intravascular large B-cell lymphoma with a t(3;14)(q27;q32) translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12861069" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Multicolor karyotyping and clinicopathological analysis of three intravascular lymphoma cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32763919" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cytogenetic complexity and heterogeneity in intravascular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29514783" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512416" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414473" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute intracerebral hemorrhage in intravascular lymphoma: a serious infusion related adverse event of rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955689" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A case of intravascular large B-cell lymphoma mimicking erythema nodosum: the importance of multiple skin biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543290" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17129231" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 18F-Fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17513823" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pulmonary intravascular large B-cell lymphoma as a cause of severe hypoxemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18053461" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18406005" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The use of blind skin biopsy in the diagnosis of intravascular B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26291417" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Usefulness of Random Skin Biopsy as a Diagnostic Tool of Intravascular Lymphoma Presenting With Fever of Unknown Origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24932279" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Benefits of skin biopsy of senile hemangioma in intravascular large B-cell lymphoma: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30647028" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31541748" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Skin biopsy in the diagnosis of intravascular lymphoma: A retrospective diagnostic accuracy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30609011" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: a clinicopathological study of 25 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28668948" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Limited Role of Random Skin Biopsy in the Diagnosis of Intravascular Lymphoma in Adult Patients with Hemophagocytic Lymphohistiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28626893" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Random skin biopsy in the diagnosis of intravascular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26871422" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Three Cases of Intravascular Large B-Cell Lymphoma Detected in a Biopsy of Skin Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30261371" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Random Skin Biopsies Before Brain Biopsy for Intravascular Large B-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20212240" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : FDG-PET a pivotal imaging modality for diagnosis of stroke-onset intravascular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20212240" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : FDG-PET a pivotal imaging modality for diagnosis of stroke-onset intravascular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26178620" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cutaneous Intravascular NK/T-cell lymphoma mimic panniculitis clinically, case report and literature brief review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931234" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Intravascular NK/T-cell lymphoma: a report of five cases with cutaneous manifestation from China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32802165" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Analysis of clinicopathological features and prognostic factors of non-Hodgkin's intravascular large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32566654" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318799" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Intralymphatic histiocytosis. A clinicopathologic study of 16 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25319987" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Benign atypical intravascular CD30+ T-cell proliferation: a recently described reactive lymphoproliferative process and simulator of intravascular lymphoma: report of a case associated with lichen sclerosus and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943898" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chromosomal aberrations in intravascular lymphomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951396" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438828" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Successful treatment of intravascular malignant lymphomatosis with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18838697" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242397" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496649" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15224358" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Usefulness of FDG-PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
